Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
OBJECTIVE:The objective of this study was to evaluate the antitumor effects of lurbinectedin as a single agent or in combination with existing anticancer agents for clear cell carcinoma (CCC) of the ovary, which is regarded as an aggressive, chemoresistant, histological subtype. METHODS:Using human...
Main Authors: | Ryoko Takahashi, Seiji Mabuchi, Mahiru Kawano, Tomoyuki Sasano, Yuri Matsumoto, Hiromasa Kuroda, Katsumi Kozasa, Kae Hashimoto, Kenjiro Sawada, Tadashi Kimura |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4795692?pdf=render |
Similar Items
-
The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations
by: Eriko Yokoi, et al.
Published: (2019-12-01) -
Effect of Japanese Kampo Medicine Therapy for Menopausal Symptoms after Treatment of Gynecological Malignancy
by: Akihiko Yoshimura, et al.
Published: (2018-01-01) -
Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
by: Kotaro Shimura, et al.
Published: (2021-01-01) -
Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
by: Dario P. Anobile, et al.
Published: (2021-05-01) -
Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies
by: Seiji Mabuchi, et al.
Published: (2020-03-01)